利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.018 秒)

    Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof
    2.
    发明授权
    Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof 有权
    红细胞生成素模拟肽衍生物及其药用盐，的制备及应用

    公开(公告)号：US08642545B2

    公开(公告)日：2014-02-04

    申请号：US12747818

    申请日：2008-11-24

    申请人： Aifeng Lü ,  Changan Sun ,  Tao Jiang ,  Wentao Wu ,  Yali Wang

    发明人： Aifeng Lü ,  Changan Sun ,  Tao Jiang ,  Wentao Wu ,  Yali Wang

    IPC分类号： C07K14/505

    CPC分类号： C07K14/505 ,  A61K47/55 ,  A61K47/60

    摘要： What is provided is EPO mimetic peptide derivatives defined as formula (I) and their pharmaceutical salts, the preparation thereof, wherein R1, R2, R3, R4, R5, n1, n2 are defined as described in description. A composition comprising of an EPO mimetic peptide derivative defined as formula (I) and its pharmaceutical salt. The uses of the derivatives and their pharmaceutical salts, as well as the uses of the compositions described above in treatment of diseases characterized by a deficiency of EPO or a low or defective red blood cell population. R1—R2—(CH2)n1—R3—(CH2)n2—R4—R5  (I)

    摘要翻译： 提供的定义为式（I）的EPO模拟肽衍生物及其药物盐及其制备方法，其中R1，R2，R3，R4，R5，n1，n2如描述中所述定义。 包含由式（I）定义的EPO模拟肽衍生物及其药物盐的组合物。 衍生物及其药物盐的用途，以及上述组合物在治疗由EPO缺乏或低或有缺陷的红细胞群体特征的疾病的用途中的用途。 R1-R2-（CH2）n1-R3-（CH2）n2-R4-R5（I）

    GLP-1 analogues and their pharmaceutical salts and uses
    3.
    发明授权
    GLP-1 analogues and their pharmaceutical salts and uses 有权
    GLP-1类似物及其药物盐和用途

    公开(公告)号：US08614182B2

    公开(公告)日：2013-12-24

    申请号：US13362593

    申请日：2012-01-31

    申请人： Yali Wang ,  Aifeng Lü ,  Changan Sun ,  Hengli Yuan

    发明人： Yali Wang ,  Aifeng Lü ,  Changan Sun ,  Hengli Yuan

    IPC分类号： A61K38/26 ,  A61K38/00 ,  A61K38/16 ,  A61K38/12 ,  C07K1/00

    CPC分类号： A61K38/26 ,  C07K14/605 ,  G01N33/566

    摘要： This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24-Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-Lys  Formula (I)—SEQ ID NO: 238

    摘要翻译： 本发明公开了GLP-1类似物及其药物盐，其中GLP-1类似物包含通式（I）的氨基酸序列，其中Lys表示具有亲脂性酸的经修饰的赖氨酸。 本发明提供的GLP-1类似物具有人GLP-1的功能，与人GLP-1相比体内的半衰期更长。 这些化合物和组合物的用途包括治疗非胰岛素依赖性糖尿病，胰岛素依赖型糖尿病和肥胖症。 X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Ph​​e-Ile-X24-Trp- Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-LysFormula（I）-SEQ ID NO：238

    GLP-1 ANALOGUES AND THEIR PHARMACEUTICAL SALTS AND USES
    4.
    发明申请
    GLP-1 ANALOGUES AND THEIR PHARMACEUTICAL SALTS AND USES 有权
    GLP-1类似物及其药物销售和用途

    公开(公告)号：US20120196798A1

    公开(公告)日：2012-08-02

    申请号：US13362593

    申请日：2012-01-31

    申请人： Yali Wang ,  Aifeng Lü ,  Changan Sun ,  Hengli Yuan

    发明人： Yali Wang ,  Aifeng Lü ,  Changan Sun ,  Hengli Yuan

    IPC分类号： A61K38/26 ,  A61P3/10 ,  A61P3/04 ,  C07K14/605

    CPC分类号： A61K38/26 ,  C07K14/605 ,  G01N33/566

    摘要： This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. (I)    X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12- X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24-Trp- Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39- Lys                                  

    摘要翻译： 本发明公开了GLP-1类似物及其药物盐，其中GLP-1类似物包含通式（I）的氨基酸序列，其中Lys表示具有亲脂性酸的经修饰的赖氨酸。 本发明提供的GLP-1类似物具有人GLP-1的功能，与人GLP-1相比体内的半衰期更长。 这些化合物和组合物的用途包括治疗非胰岛素依赖性糖尿病，胰岛素依赖型糖尿病和肥胖症。 （I）X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Ph​​e-Ile-X24 -Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-Lys

    GLP-1 ANALOGUES AND THEIR PHARMACEUTICAL SALTS AND USES
    5.
    发明申请
    GLP-1 ANALOGUES AND THEIR PHARMACEUTICAL SALTS AND USES 审中-公开
    GLP-1类似物及其药物销售和用途

    公开(公告)号：US20120129768A1

    公开(公告)日：2012-05-24

    申请号：US13388056

    申请日：2010-07-29

    申请人： Yali Wang ,  Aifeng Lü ,  Changan Sun ,  Hengli Yuan

    发明人： Yali Wang ,  Aifeng Lü ,  Changan Sun ,  Hengli Yuan

    IPC分类号： A61K38/26 ,  A61P3/10 ,  A61P3/04 ,  C07K14/605

    CPC分类号： C07K14/605 ,  A61K38/00

    摘要： This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. (I) X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12- X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24- Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36- X37-X38-X39-Lys

    摘要翻译： 本发明公开了GLP-1类似物及其药物盐，其中GLP-1类似物包含通式（I）的氨基酸序列，其中Lys表示具有亲脂性酸的经修饰的赖氨酸。 本发明提供的GLP-1类似物具有人GLP-1的功能，与人GLP-1相比体内的半衰期更长。 这些化合物和组合物的用途包括治疗非胰岛素依赖性糖尿病，胰岛素依赖型糖尿病和肥胖症。 （I）X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Ph​​e-Ile-X24 - Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-Lys